Expression of a-disintegrin and metalloproteinase 10 correlates with grade of malignancy in human glioma

Qu,Min; Qiu,Bo; Xiong,Wende; Chen,Dong; Wu,Anhua

doi:10.3892/ol.2015.2993

Expression of a-disintegrin and metalloproteinase 10 correlates with grade of malignancy in human glioma

Authors:
- Min Qu
- Bo Qiu
- Wende Xiong
- Dong Chen
- Anhua Wu
View Affiliations

Affiliations: Department of Neurosurgery, The Central Hospital of Dalian City, Dalian, Liaoning 116033, P.R. China, Department of Neurosurgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: February 27, 2015 https://doi.org/10.3892/ol.2015.2993
Pages: 2157-2162

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to determine the expression of a‑disintegrin and metalloproteinase 10 (ADAM10) in human glioma tissues from surgical specimens and discuss its possible significance in glioma biology. A total of 43 glioma specimens obtained from patients between 2007 and 2010 were collected and a series of assays were performed. Of these, 22 cases were low‑grade gliomas, while 21 cases were high‑grade gliomas. In addition, 20 cases of meningioma were used as the control group. Reverse transcription‑polymerase chain reaction (RT‑PCR), western blot analysis and immunohistochemistry were used to determine the mRNA and protein expression levels of ADAM10. Besides the quantitative analysis, histological observations were also performed to localize ADAM10 expression in glioma cells. The RT‑PCR and western blot analysis results demonstrated increased ADAM10 expression in the low‑grade glioma samples compared with the control (P<0.05), while ADAM10 expression was further increased in the high‑grade glioma samples (P<0.01 vs. control; P<0.05 vs. low‑grade glioma), indicating that the mRNA and protein expression levels of ADAM10 were malignancy‑dependent. The immunohistochemical analysis revealed that the ADAM10 protein was located on both the tumor cell membrane and blood vessel walls within tumor tissues. In conclusion, these results indicated that ADAM10 expression correlates with the grade of malignancy in human glioma from surgical specimens. In addition, the fact that ADAM10 protein was expressed on cell membranes and blood vessel walls within tumor tissues, indicates that its expression may be associated with invasive tumor growth and peritumoral edema formation.

View Figures

View References

1	Ohgaki H and Kleihues P: Epidemiology and etiology of gliomas. Acta Neuropathol. 109:93–108. 2005. View Article : Google Scholar : PubMed/NCBI
2	Stupp R, Mason WP, van den Bent MJ, et al: European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
3	Qiu B, Zhang D, Wang Y, et al: Interleukin-6 is overexpressed and augments invasiveness of human glioma stem cells in vitro. Clin Exp Metastasis. 30:1009–1018. 2013. View Article : Google Scholar : PubMed/NCBI
4	Qiu B, Zhang D, Tao J, Tie X, Wu A and Wang Y: Human brain glioma stem cells are more invasive than their differentiated progeny cells in vitro. J Clin Neurosci. 19:130–134. 2012. View Article : Google Scholar : PubMed/NCBI
5	Stylli SS, Howes M, MacGregor L, Rajendra P and Kaye AH: Photodynamic therapy of brain tumours: evaluation of porphyrin uptake versus clinical outcome. J Clin Neurosci. 11:584–596. 2004. View Article : Google Scholar : PubMed/NCBI
6	Stylli SS, Kaye AH, MacGregor L, Howes M and Rajendra P: Photodynamic therapy of high grade glioma - long term survival. J Clin Neurosci. 12:389–398. 2005. View Article : Google Scholar : PubMed/NCBI
7	Park DM and Rich JN: Biology of glioma cancer stem cells. Mol Cells. 28:7–12. 2009. View Article : Google Scholar : PubMed/NCBI
8	Cuddapah VA, Robel S, Watkins S and Sontheimer H: A neurocentric perspective on glioma invasion. Nat Rev Neurosci. 15:455–465. 2014. View Article : Google Scholar : PubMed/NCBI
9	Coniglio SJ and Segall JE: Review: molecular mechanism of microglia stimulated glioblastoma invasion. Matrix Biol. 32:372–380. 2013. View Article : Google Scholar : PubMed/NCBI
10	Kaczarek E, Zapf S, Bouterfa H, Tonn JC, Westphal M and Giese A: Dissecting glioma invasion: interrelation of adhesion, migration and intercellular contacts determine the invasive phenotype. Int J Dev Neurosci. 17:625–641. 1999. View Article : Google Scholar : PubMed/NCBI
11	Stamenkovic I: Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol. 200:448–464. 2003. View Article : Google Scholar : PubMed/NCBI
12	Bulstrode H, Jones LM, Siney EJ, et al: A-Disintegrin and Metalloprotease (ADAM) 10 and 17 promote self-renewal of brain tumor sphere forming cells. Cancer Lett. 326:79–87. 2012. View Article : Google Scholar : PubMed/NCBI
13	Edwards DR, Handsley MM and Pennington CJ: The ADAM metalloproteinases. Mol Aspects Med. 29:258–289. 2008. View Article : Google Scholar : PubMed/NCBI
14	Pruessmeyer J and Ludwig A: The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer. Semin Cell Dev Biol. 20:164–174. 2009. View Article : Google Scholar : PubMed/NCBI
15	Huovila AP, Turner AJ, Pelto-Huikko M, Kӓrkkӓinen I and Ortiz RM: Shedding light on ADAM metalloproteinases. Trends Biochem Sci. 30:413–422. 2005. View Article : Google Scholar : PubMed/NCBI
16	Seals DF and Courtneidge SA: The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 17:7–30. 2003. View Article : Google Scholar : PubMed/NCBI
17	Zhao R, Ni D, Tian Y, Ni B and Wang A: Aberrant ADAM10 expression correlates with osteosarcoma progression. Eur J Med Res. 19:92014. View Article : Google Scholar : PubMed/NCBI
18	Armanious H, Gelebart P, Anand M, Belch A and Lai R: Constitutive activation of metalloproteinase ADAM10 in mantle cell lymphoma promotes cell growth and activates the TNFα/NFκB pathway. Blood. 117:6237–6246. 2011. View Article : Google Scholar : PubMed/NCBI
19	Zhang W, Liu S, Liu K, et al: A disintegrin and metalloprotease (ADAM)10 is highly expressed in hepatocellular carcinoma and is associated with tumour progression. J Int Med Res. 42:611–618. 2014. View Article : Google Scholar : PubMed/NCBI
20	Ko SY, Lin SC, Wong YK, Liu CJ, Chang KW and Liu TY: Increase of disintergin metalloprotease 10 (ADAM10) expression in oral squamous cell carcinoma. Cancer Lett. 245:33–43. 2007. View Article : Google Scholar : PubMed/NCBI
21	Kleihues P, Louis DN, Scheithauer BW, et al: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 61:215–229. 2002.PubMed/NCBI
22	Qiu B, Li X, Sun X, et al: Overexpression of aquaporin-1 aggravates hippocampal damage in mouse traumatic brain injury models. Mol Med Rep. 9:916–922. 2014.PubMed/NCBI
23	Qiu B, Sun X, Zhang D, Wang Y, Tao J and Ou S: TRAIL and paclitaxel synergize to kill U87 cells and U87-derived stem-like cells in vitro. Int J Mol Sci. 13:9142–9156. 2012. View Article : Google Scholar : PubMed/NCBI
24	Wolfsberg TG and White JM: ADAMs in fertilization and development. Dev Biol. 180:389–401. 1996. View Article : Google Scholar : PubMed/NCBI
25	Yoshimura T, Tomita T, Dixon MF, Axon AT, Robinson PA and Crabtree JE: ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori-infected, normal, and neoplastic gastric mucosa. J Infect Dis. 185:332–340. 2002. View Article : Google Scholar : PubMed/NCBI
26	Rocks N, Paulissen G, El Hour M, et al: Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie. 90:369–379. 2008. View Article : Google Scholar : PubMed/NCBI
27	Wildeboer D, Naus S, Amy Sang QX, Bartsch JW and Pagenstecher A: Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness. J Neuropathol Exp Neurol. 65:516–527. 2006. View Article : Google Scholar : PubMed/NCBI
28	Kodama T, Ikeda E, Okada A, et al: ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am J Pathol. 165:1743–1753. 2004. View Article : Google Scholar : PubMed/NCBI
29	D'Abaco GM, Ng K, Paradiso L, Godde NJ, Kaye A and Novak U: ADAM22, expressed in normal brain but not in high-grade gliomas, inhibits cellular proliferation via the disintegrin domain. Neurosurgery. 58:179–186. 2006. View Article : Google Scholar : PubMed/NCBI
30	Zheng X, Jiang F, Katakowski M, et al: Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness. Cancer Sci. 98:674–684. 2007. View Article : Google Scholar : PubMed/NCBI
31	McCulloch DR, Akl P, Samaratunga H, Herington AC and Odorico DM: Expression of the disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP. Clin Cancer Res. 10:314–323. 2004. View Article : Google Scholar : PubMed/NCBI
32	Schulz B, Pruessmeyer J, Maretzky T, et al: ADAM10 regulates endothelial permeability and T-Cell transmigration by proteolysis of vascular endothelial cadherin. Circ Res. 102:1192–1201. 2008. View Article : Google Scholar : PubMed/NCBI
33	Millichip MI, Dallas DJ, Wu E, Dale S and McKie N: The metallo-disintegrin ADAM10 (MADM) from bovine kidney has type IV collagenase activity in vitro. Biochem Biophys Res Commun. 245:594–598. 1998. View Article : Google Scholar : PubMed/NCBI
34	Kohutek ZA, diPierro CG, Redpath GT and Hussaini IM: ADAM-10-mediated N-cadherin cleavage is protein kinase C-alpha dependent and promotes glioblastoma cell migration. J Neurosci. 29:4605–4615. 2009. View Article : Google Scholar : PubMed/NCBI
35	Yang CL, Jiang FQ, Xu F and Jiang GX: ADAM10 overexpression confers resistance to doxorubicin-induced apoptosis in hepatocellular carcinoma. Tumour Biol. 33:1535–1541. 2012. View Article : Google Scholar : PubMed/NCBI